{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:53:43Z","timestamp":1790916823563,"version":"4.1.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":221,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101368","type":"journal-article","created":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T10:58:41Z","timestamp":1786877921000},"page":"101368","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Real-world efficacy and sequential therapy patterns after avelumab maintenance in metastatic urothelial carcinoma: a Brazilian multicenter retrospective cohort study"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-8334-9310","authenticated-orcid":false,"given":"Isabelle E.","family":"Cohen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena F.","family":"Bruzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia C. e S.","family":"Gontijo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Fernanda S.S.","family":"de Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela C.K.","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmim P.","family":"Dias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5014-573X","authenticated-orcid":false,"given":"Haonne S.","family":"Abboud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5194-8321","authenticated-orcid":false,"given":"Vinicius","family":"Freire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5166-848X","authenticated-orcid":false,"given":"Daniel","family":"Herchenhorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ctarc.2026.101368_bib0001","doi-asserted-by":"crossref","first-page":"356","DOI":"10.21037\/tau-20-960","article-title":"Population-based outcome of muscle-invasive bladder cancer following radical cystectomy: who can benefit from adjuvant chemotherapy?","volume":"10","author":"Tian","year":"2021","journal-title":"Transl. Androl. Urol."},{"key":"10.1016\/j.ctarc.2026.101368_bib0002","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/s41585-024-00872-0","article-title":"The evolving treatment landscape of metastatic urothelial cancer","volume":"21","author":"Roviello","year":"2024","journal-title":"Nat. Rev. Urol."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101368_bib0003","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3390\/cancers17030509","article-title":"Split-dose cisplatin use, eligibility criteria, and drivers for treatment choice in patients with locally advanced or metastatic urothelial carcinoma: results of a large international physician survey","volume":"17","author":"O'Dwyer","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"13","key":"10.1016\/j.ctarc.2026.101368_bib0004","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.ctarc.2026.101368_bib0005","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.22.01792","article-title":"Avelumab first-line maintenance for advanced urothelial carcinoma: results from the JAVELIN Bladder 100 trial after \u22652 years of follow-up","volume":"41","author":"Schmid","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101368_bib0006","doi-asserted-by":"crossref","first-page":"11107","DOI":"10.2147\/DDDT.S560518","article-title":"Infusion-related reactions among cancer patients receiving immune checkpoint inhibitors: the ARON-MOUSEION-013 systematic review and meta-analysis","volume":"19","author":"Vitale","year":"2025","journal-title":"Drug Des. Devel. Ther."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101368_bib0007","doi-asserted-by":"crossref","DOI":"10.1007\/s10555-026-10327-0","article-title":"Hyponatremia in cancer patients receiving immune checkpoint inhibitors: the ARON-MOUSEION-014 meta-analysis","volume":"45","author":"Vitale","year":"2026","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.ctarc.2026.101368_bib0008","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.clnesp.2025.10.031","article-title":"Decreased appetite in cancer patients treated with immune checkpoint inhibitors (icis): the MOUSEION-012 systematic review and meta-analysis","volume":"70","author":"Vitale","year":"2025","journal-title":"Clin. Nutr. ESPEN"},{"issue":"2","key":"10.1016\/j.ctarc.2026.101368_bib0009","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.euo.2024.09.014","article-title":"Real-world study of avelumab first-line maintenance treatment in patients with advanced urothelial carcinoma in France: overall results from the noninterventional AVENANCE study and analysis of outcomes by second-line treatment","volume":"8","author":"Barth\u00e9l\u00e9my","year":"2025","journal-title":"Eur. Urol. Oncol."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101368_bib0010","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3390\/curroncol32040187","article-title":"Real-world clinical outcomes with first-line systemic treatment and avelumab maintenance in US patients with locally advanced or metastatic urothelial carcinoma: the SPEAR Bladder-II study","volume":"32","author":"Sura","year":"2025","journal-title":"Curr. Oncol."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101368_bib0011","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s11523-024-01099-0","article-title":"Enfortumab vedotin following platinum chemotherapy and avelumab maintenance in patients with metastatic urothelial carcinoma: retrospective data from the ARON-2EV study","volume":"19","author":"Fiala","year":"2024","journal-title":"Target. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101368_bib0012","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-026-16109-9","article-title":"Enfortumab vedotin in ECOG-PS 2 advanced urothelial carcinoma patients: a real-world study from the Aron-2EV Project","volume":"26","author":"Rizzo","year":"2026","journal-title":"BMC Cancer"},{"issue":"21","key":"10.1016\/j.ctarc.2026.101368_bib0013","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","article-title":"Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer","volume":"23","author":"von der Maase","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101368_bib0014","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1200\/JCO.2011.37.3571","article-title":"Randomized phase II\/III trial assessing gemcitabine\/carboplatin and methotrexate\/carboplatin\/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986","volume":"30","author":"De Santis","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101368_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2025.102453","article-title":"Real-world outcomes of enfortumab vedotin and pembrolizumab in advanced urothelial carcinoma: a multicenter retrospective analysis","volume":"23","author":"Jain","year":"2025","journal-title":"Clin. Genitourin. Cancer"},{"issue":"10","key":"10.1016\/j.ctarc.2026.101368_bib0016","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101368_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2024.102238","article-title":"Avelumab first-line maintenance for locally advanced or metastatic urothelial carcinoma: results from the real-world US PATRIOT-II study","volume":"22","author":"Grivas","year":"2024","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.ctarc.2026.101368_bib0018","article-title":"READY: real-world data from an Italian compassionate use program of avelumab first-line maintenance for locally advanced or metastatic urothelial carcinoma","volume":"5","author":"Antonuzzo","year":"2024","journal-title":"ESMO Real World Data Digit Oncol."},{"key":"10.1016\/j.ctarc.2026.101368_bib0019","article-title":"JAVEMACS: a real-world study of avelumab maintenance therapy for advanced urothelial carcinoma in Japan","volume":"10","author":"Kitamura","year":"2025","journal-title":"ESMO Real World Data Digit. Oncol."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101368_bib0020","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.1215","article-title":"Significance of PD-L1 in metastatic urothelial carcinoma treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"7","author":"Maiorano","year":"2024","journal-title":"JAMA Netw. Open."},{"issue":"21","key":"10.1016\/j.ctarc.2026.101368_bib0021","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","article-title":"Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma","volume":"389","author":"Loriot","year":"2023","journal-title":"N. Engl. J. Med."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226002790?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226002790?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:00:41Z","timestamp":1790913641000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226002790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":21,"alternative-id":["S2468294226002790"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101368","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world efficacy and sequential therapy patterns after avelumab maintenance in metastatic urothelial carcinoma: a Brazilian multicenter retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101368","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101368"}}